VBI Vaccines Inc. Daily Stock Analysis

Daily Stock Analysis, VBIV, VBI Vaccines Inc, priceseries

VBI Vaccines Inc. Daily Stock Analysis
Stock Information
Open
1.29
Close
1.33
High
1.49
Low
1.29
Previous Close
1.31
Daily Price Gain
0.02
YTD High
2.47
YTD High Date
Jan 3, 2022
YTD Low
1.21
YTD Low Date
Feb 24, 2022
YTD Price Change
-1.14
YTD Gain
-46.15%
52 Week High
4.31
52 Week High Date
Jun 29, 2021
52 Week Low
1.21
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-1.77
52 Week Gain
-57.10%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 20. 2017
3.45
Feb 14. 2017
3.86
17 Trading Days
11.75%
Link
LONG
Feb 15. 2017
4.00
Mar 17. 2017
5.93
21 Trading Days
48.27%
Link
LONG
Nov 1. 2017
3.72
Dec 4. 2017
4.59
22 Trading Days
23.49%
Link
LONG
Sep 26. 2018
1.99
Oct 9. 2018
2.18
9 Trading Days
9.40%
Link
LONG
Dec 26. 2018
1.42
Jan 10. 2019
1.57
10 Trading Days
10.41%
Link
LONG
Jun 24. 2019
1.29
Jun 25. 2019
1.39
1 Trading Days
7.75%
Link
LONG
Dec 20. 2019
0.98
Dec 27. 2019
1.07
4 Trading Days
9.75%
Link
LONG
Apr 9. 2020
0.96
Apr 22. 2020
1.10
8 Trading Days
14.58%
Link
LONG
May 8. 2020
1.36
May 27. 2020
2.06
12 Trading Days
51.49%
Link
LONG
Jul 7. 2020
3.36
Jul 24. 2020
4.88
13 Trading Days
45.26%
Link
LONG
Nov 25. 2020
2.72
Dec 9. 2020
3.00
9 Trading Days
10.24%
Link
LONG
Jan 28. 2021
3.26
Feb 12. 2021
3.93
11 Trading Days
20.44%
Link
LONG
Apr 21. 2021
2.81
May 4. 2021
2.97
9 Trading Days
5.82%
Link
LONG
Jun 7. 2021
3.46
Jun 21. 2021
3.75
10 Trading Days
8.52%
Link
LONG
Aug 23. 2021
3.10
Sep 3. 2021
3.39
9 Trading Days
9.41%
Link
Company Information
Stock Symbol
VBIV
Exchange
NasdaqCM
Company URL
http://www.vbivaccines.com
Company Phone
6178303031
CEO
Jeff Baxter
Headquarters
Massachusetts
Business Address
222 THIRD STREET, SUITE 2241, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000704159
About

VBI Vaccines, Inc. is a biopharmaceutical company, which develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology. Its products portfolio includes Sci-B-Vac, HBV, CMV Vaccine, GBM Immunotherapy and RSV Vaccine. The company is headquartered in Cambridge, MA.

Description

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading